Showing results (1531-1540 of 3,085) with videos related to

Sort By:
Pageof 309
Drug Safety|September 12, 2023
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational StudiesTsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, et al.
Drug Safety|July 27, 2017
Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in JapanKazuki Ozawa, Akiyo Hineno, Tomomi Kinoshita, et al.
Drug Safety|February 22, 2015
Comparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationYasha S Modi, Carley Tanchon, Justis P Ehlers
Drug Safety|October 7, 2020
Artificial Intelligence, Real-World Automation and the Safety of MedicinesAndrew Bate, Steve F Hobbiger
Drug Safety|July 2, 2026
Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution InstrumentsJack Janetzki, Lisa Kalisch-Ellett, Nicole Pratt, et al.
Drug Safety|October 29, 2021
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort StudyJulie Rouette, Hui Yin, Emily G McDonald, et al.
Drug Safety|July 14, 2026
Enhancing Disease Surveillance and Pharmacovigilance Practices for RTS,S/AS01E Malaria Vaccine Rollout in Ghana, Kenya, and Malawi: Strategies, Impact, Challenges, and Lessons LearnedValérie Haine, Tene-Alima Essoh, Caroline Perrin Franck, et al.
Drug Safety|August 1, 2026
AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety SurveillanceCatherine Tregunno, Quentin Deraedt, Susanna Cuadripani, et al.
Drug Safety|August 26, 2026
Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIVG Niklas Norén, Julie Durand, Vijay Kara, et al.
Drug Safety|September 3, 2026
Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy MaterialsAmeet Sarpatwari, Frazer A Tessema, Mayookha Mitra-Majumdar, et al.
Pageof 309